Concourse Financial Group Securities, Inc. Biotechnology

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
TSHA Taysha Gene Therapies, Inc.	$143M	$0 100.0% of portfolio	0	Q2 2025 New
TNYA Tenaya Therapeutics, Inc.	$46.7M	$0 100.0% of portfolio	0	Q2 2025 New
TERN Terns Pharmaceuticals, Inc.	$276M	$0 100.0% of portfolio	0	Q2 2025 New
TGTX Tg Therapeutics, Inc.	$4.26B	$0 100.0% of portfolio	0	Q2 2025 New
TBPH Theravance Biopharma, Inc.	$927M	$0 100.0% of portfolio	0	Q2 2025 New
THRD Third Harmonic Bio, Inc.	$217M	$0 100.0% of portfolio	0	Q2 2025 New
TLSA Tiziana Life Sciences LTD	$181M	$0 100.0% of portfolio	0	Q2 2025 New
TVTX Travere Therapeutics, Inc.	$1.16B	$0 100.0% of portfolio	0	Q2 2025 New
TRVI Trevi Therapeutics, Inc.	$426M	$0 100.0% of portfolio	0	Q2 2025 New
TCDA Tricida, Inc.	$557K	$0 100.0% of portfolio	0	Q2 2025 New
TCRX T Scan Therapeutics, Inc.	$34.1M	$0 100.0% of portfolio	0	Q2 2025 New
TYRA Tyra Biosciences, Inc.	$532M	$0 100.0% of portfolio	0	Q2 2025 New
RARE Ultragenyx Pharmaceutical Inc.	$2.24B	$0 100.0% of portfolio	0	Q2 2025 New
QURE Uni Qure N.V.	$763M	$0 100.0% of portfolio	0	Q2 2025 New
UTHR United Therapeutics Corp	$18.4B	$0 100.0% of portfolio	0	Q2 2025 New
URGN Uro Gen Pharma Ltd.	$443M	$0 100.0% of portfolio	0	Q2 2025 New
VACC Vaccitech PLC	$127M	$0 100.0% of portfolio	0	Q2 2025 New
VALN Valneva Se	$612M	$0 100.0% of portfolio	0	Q2 2025 New
VNDA Vanda Pharmaceuticals Inc.	$268M	$0 100.0% of portfolio	0	Q2 2025 New
VXRT Vaxart, Inc.	$49.3M	$0 100.0% of portfolio	0	Q2 2025 New
PCVX Vaxcyte, Inc.	$1.87B	$0 100.0% of portfolio	0	Q2 2025 New
VTYX Ventyx Biosciences, Inc.	$136M	$0 100.0% of portfolio	0	Q2 2025 New
VERA Vera Therapeutics, Inc.	$585M	$0 100.0% of portfolio	0	Q2 2025 New
VCYT Veracyte, Inc.	$2.16B	$0 100.0% of portfolio	0	Q2 2025 New
VCEL Vericel Corp	$1.63B	$0 100.0% of portfolio	0	Q2 2025 New
VRNA Verona Pharma PLC	$6.46B	$0 100.0% of portfolio	0	Q2 2025 New
VRCA Verrica Pharmaceuticals Inc.	$327M	$0 100.0% of portfolio	0	Q2 2025 New
VRTX Vertex Pharmaceuticals Inc	$103B	$0 100.0% of portfolio	0	Q2 2025 New
VERU Veru Inc.	$260M	$0 100.0% of portfolio	0	Q2 2025 New
VERV Verve Therapeutics, Inc.	$667M	$0 100.0% of portfolio	0	Q2 2025 New
VIGL Vigil Neuroscience, Inc.	$228M	$0 100.0% of portfolio	0	Q2 2025 New
VKTX Viking Therapeutics, Inc.	$2.07B	$0 100.0% of portfolio	0	Q2 2025 New
VIR Vir Biotechnology, Inc.	$663M	$0 100.0% of portfolio	0	Q2 2025 New
VRDN Viridian Therapeutics, Inc.\De	$733M	$0 100.0% of portfolio	0	Q2 2025 New
VOR Vor Biopharma Inc.	$75.7M	$0 100.0% of portfolio	0	Q2 2025 New
VYGR Voyager Therapeutics, Inc.	$130M	$0 100.0% of portfolio	0	Q2 2025 New
VYNE Vyne Therapeutics Inc.	$18.6M	$0 100.0% of portfolio	0	Q2 2025 New
WVE Wave Life Sciences Ltd.	$833M	$0 100.0% of portfolio	0	Q2 2025 New
HOWL Werewolf Therapeutics, Inc.	$39.3M	$0 100.0% of portfolio	0	Q2 2025 New
WINT Windtree Therapeutics Inc	$2.14M	$0 100.0% of portfolio	0	Q2 2025 New
XBIT X Biotech Inc.	$97.4M	$0 100.0% of portfolio	0	Q2 2025 New
XNCR Xencor Inc	$510M	$0 100.0% of portfolio	0	Q2 2025 New
XENE Xenon Pharmaceuticals Inc.	$2.45B	$0 100.0% of portfolio	0	Q2 2025 New
XERS Xeris Biopharma Holdings, Inc.	$1.06B	$0 100.0% of portfolio	0	Q2 2025 New
XLO Xilio Therapeutics, Inc.	$19M	$0 100.0% of portfolio	0	Q2 2025 New
XOMA Xoma Corp	$372M	$0 100.0% of portfolio	0	Q2 2025 New
XTLB Xtl Biopharmaceuticals LTD	$6.76M	$0 100.0% of portfolio	0	Q2 2025 New
YMAB Y M Abs Therapeutics, Inc.	$374M	$0 100.0% of portfolio	0	Q2 2025 New
ZLAB Zai Lab LTD	$3.26B	$0 100.0% of portfolio	0	Q2 2025 New
ZNTL Zentalis Pharmaceuticals, Inc.	$98M	$0 100.0% of portfolio	0	Q2 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.